Amicus Therapeutics is building momentum with strong sales growth from GALAFOLD and POMBILITI/OPFOLDA. Click here to find out ...

Shares of Amicus Therapeutics (FOLD) have gained 12.9% over the past four weeks to close the last trading session at $6.83, ...

Amicus Therapeutics (FOLD) could be a solid choice for investors given the company's remarkably improving earnings outlook.

Q2 2025 Total Revenue of $154.7M, up 18% at CER Galafold® Q2 Revenue of $128.9M, up 12% at CER Pombiliti® + Opfolda® Q2 Revenue of $25.8M, up 58% at CER Reiterating 2025 Financial Guidance including ...

Amicus Therapeutics, Inc. (NASDAQ: FOLD) is one of the best strong buy stocks to buy under $10. In a report released on July ...

Learn more about whether ADMA Biologics, Inc. or Amicus Therapeutics, Inc. is a better investment based on AAII's A+ Investor ...

Amicus Therapeutics (NASDAQ:FOLD) is gearing up to announce its quarterly earnings on Thursday, 2025-05-01. Here's a quick overview of what investors should know before the release. Analysts are ...

Amicus Therapeutics reported a remarkable 2024 with total revenue reaching approximately $528.5 million, reflecting a 32% year-over-year growth, driven mainly by strong demand for its products ...

Amicus Therapeutics posted a loss of 51 cents a share in FY2023 on just over $399 million in revenue. The current analyst firm consensus has losses being cut by more than half to 21 cents a share ...

Amicus Therapeutics FOLD is gearing up to announce its quarterly earnings on Thursday, 2025-05-01. Here's a quick overview of what investors should know before the release. Analysts are estimating ...